Ahead of the Bell: Analyst upgrades Bristol-Myers
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker. Full story

